{
  "id": "5e44c18648dab47f2600001f",
  "type": "yesno",
  "question": "Does gavestinel improve outcomes of stroke patients?",
  "ideal_answer": "No. In a randomized clinical trial, treatment with gavestinel within 6 hours of acute ischaemic stroke did not improve outcome.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/15831831",
    "http://www.ncbi.nlm.nih.gov/pubmed/10859040",
    "http://www.ncbi.nlm.nih.gov/pubmed/11277826",
    "http://www.ncbi.nlm.nih.gov/pubmed/16340185",
    "http://www.ncbi.nlm.nih.gov/pubmed/15032709",
    "http://www.ncbi.nlm.nih.gov/pubmed/11727452",
    "http://www.ncbi.nlm.nih.gov/pubmed/15243144"
  ],
  "snippets": [
    {
      "text": "CONCLUSION: Consistent with the clinical outcomes in the GAIN trials, no effects of gavestinel on ischemic infarction was observed.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16340185",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "No effects of gavestinel on infarct volume were observed in the primary or other analyses. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16340185",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15831831",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Both trials reported that gavestinel was ineffective in ischemic stroke. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15831831",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: These observations from the combined GAIN International and GAIN Americas trials suggest that gavestinel is not of substantial benefit or harm to patients with primary intracerebral hemorrhage. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15831831",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Glutamate N-methyl-D-aspartate (NMDA) receptor antagonists such as Selfotel, Aptiganel, Gavestinel and others failed to show neuroprotective efficacy in human clinical trials or produced intolerable central nervous system adverse effects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15032709",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "METHODS: We studied all patients of the Glycine Antagonist (gavestinel) In Neuroprotection (GAIN) International Trial with ischemic stroke alive at day 7, excluding patients with hemorrhagic events and deaths from nonstroke-related causes. The GAIN International Trial was a randomized, double-blind, placebo-controlled, and parallel-group trial; because the study drug had no effect on stroke outcome, treatment groups were combined for this analysis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15243144",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Gavestinel produces no benefit for stroke patients, study finds.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11727452",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The wonder drug, gavestinel, failed to produce any significant treatment benefits for patients treated within six hours after experiencing an acute ischemic stroke, according to the recent results of a major clinical trial of the neuroprotectant. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11727452",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION: Treatment with gavestinel within 6 h of acute ischaemic stroke did not improve outcome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10859040",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION\n\nTreatment with gavestinel within 6 h of acute ischaemic stroke did not improve outcome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10859040",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION\n\nIn this study, gavestinel administered up to 6 hours after an acute ischemic stroke did not improve functional outcome at 3 months.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11277826",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Both trials reported that gavestinel was ineffective in ischemic stroke.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15831831",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION Treatment with gavestinel within 6 h of acute ischaemic stroke did not improve outcome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10859040",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Both trials reported that gavestinel was ineffective in ischemic stroke.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15831831",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Gavestinel produces no benefit for stroke patients , study finds .",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11727452",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The wonder drug, gavestinel, failed to produce any significant treatment benefits for patients treated within six hours after experiencing an acute ischemic stroke, according to the recent results of a major clinical trial of the neuroprotectant.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11727452",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The wonder drug, gavestinel, failed to produce any significant treatment benefits for patients treated within six hours after experiencing an acute ischemic stroke, according to the recent results of a major clinical trial of the neuroprotectant.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11727452",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Treatment with gavestinel within 6 h of acute ischaemic stroke did not improve outcome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10859040",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this study, gavestinel administered up to 6 hours after an acute ischemic stroke did not improve functional outcome at 3 months.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11277826",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}